Sun Shanping, Zhang Wei, Cui Zhaoqing, Chen Qi, Xie Panpan, Zhou Changxin, Liu Baoguo, Peng Xiangeng, Zhang Yang
Department of Breast Surgery, Qilu Hospital of Shandong University, Shandong, People's Republic of China ; Department of Breast and Thyroid Surgery, Liaocheng People's Hospital, Liaocheng, Shandong Province, People's Republic of China.
Department of Breast and Thyroid Surgery, Liaocheng People's Hospital, Liaocheng, Shandong Province, People's Republic of China.
Onco Targets Ther. 2015 Feb 12;8:413-9. doi: 10.2147/OTT.S73366. eCollection 2015.
High mobility group box-1 (HMGB1) is a factor regulating malignant tumorigenesis, proliferation, and metastasis, and is associated with poor clinical pathology in various human cancers. We investigated the differential concentrations of HMGB1 in tissues and sera, and their clinical value for diagnosis in patients with breast cancer, benign breast disease, and healthy individuals.
HMGB1 levels in tumor tissues, adjacent normal tissues, and benign breast disease tissues was detected via immunohistochemistry. Serum HMGB1 was measured using an enzyme-linked immunosorbent assay in 56 patients with breast cancer, 25 patients with benign breast disease, and 30 healthy control subjects. The clinicopathological features of the patients were compared. Tissues were evaluated histopathologically by pathologists.
HMGB1 levels in the tissues and sera of patients with breast cancer were significantly higher than those in patients with benign breast disease or normal individuals. The 56 cancer patients were classified as having high tissue HMGB1 levels (n=41) or low tissue HMGB1 levels (n=15), but the corresponsive serum HMGB1 in these two groups was not significantly different. HMGB1 levels in breast cancer tissues significantly correlated with differentiation grade, lymphatic metastasis, and tumor-node-metastasis stage, but not patient age, tumor size, or HER-2/neu expression; no association between serum HMGB1 levels and these clinicopathological parameters was found. The sensitivity and specificity of tissue HMGB1 levels for the diagnosis of breast cancer were 73.21% and 84.00%, respectively, while positive and negative predictive values were 91.11% and 58.33%.
HMGB1 might be involved in the development and progression of breast cancer and could be a supportive diagnostic marker for breast cancer. Serum HMGB1 could be a useful serological biomarker for diagnosis and screening of breast cancer.
高迁移率族蛋白B1（HMGB1）是一种调节恶性肿瘤发生、增殖和转移的因子，与多种人类癌症的不良临床病理特征相关。我们研究了乳腺癌患者、乳腺良性疾病患者及健康个体组织和血清中HMGB1的差异浓度及其诊断的临床价值。
采用免疫组织化学法检测肿瘤组织、癌旁正常组织及乳腺良性疾病组织中HMGB1的水平。采用酶联免疫吸附测定法检测56例乳腺癌患者、25例乳腺良性疾病患者及30例健康对照者血清中的HMGB1。比较患者的临床病理特征。病理学家对组织进行组织病理学评估。
乳腺癌患者组织和血清中的HMGB1水平显著高于乳腺良性疾病患者或正常个体。56例癌症患者被分为组织HMGB1水平高（n = 41）或低（n = 15）两组，但这两组相应的血清HMGB1无显著差异。乳腺癌组织中的HMGB1水平与分化程度、淋巴转移及肿瘤-淋巴结-转移分期显著相关，但与患者年龄、肿瘤大小或HER-2/neu表达无关；未发现血清HMGB1水平与这些临床病理参数之间存在关联。组织HMGB1水平诊断乳腺癌的敏感性和特异性分别为73.21%和84.00%，阳性预测值和阴性预测值分别为91.11%和58.33%。
HMGB1可能参与乳腺癌的发生和发展，可作为乳腺癌的辅助诊断标志物。血清HMGB1可能是一种用于乳腺癌诊断和筛查的有用血清生物标志物。
